BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1346710)

  • 1. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder.
    Lunec J; Challen C; Wright C; Mellon K; Neal DE
    Lancet; 1992 Feb; 339(8790):439-40. PubMed ID: 1346710
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
    Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
    J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder.
    Coombs LM; Pigott DA; Sweeney E; Proctor AJ; Eydmann ME; Parkinson C; Knowles MA
    Br J Cancer; 1991 Apr; 63(4):601-8. PubMed ID: 1673627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
    Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
    Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
    Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
    Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder].
    Yu D; Liu F; Liang Z
    Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):202-5. PubMed ID: 9275651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the p53 gene in carcinomas of the urinary system.
    Suzuki Y; Tamura G
    Acta Pathol Jpn; 1993 Dec; 43(12):745-50. PubMed ID: 8109252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.
    Zhau HE; Zhang X; von Eschenbach AC; Scorsone K; Babaian RJ; Ro JY; Hung MC
    Mol Carcinog; 1990; 3(5):254-7. PubMed ID: 1978777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [int-2 and c-erbB-2 gene amplification in urological cancers].
    Sato K; Kato T; Moriyama M
    Nihon Hinyokika Gakkai Zasshi; 1992 Dec; 83(12):1957-63. PubMed ID: 1361954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer.
    Gardiner RA; Samaratunga ML; Walsh MD; Seymour GJ; Lavin MF
    Urol Res; 1992; 20(2):117-20. PubMed ID: 1348155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.
    Wright C; Mellon K; Johnston P; Lane DP; Harris AL; Horne CH; Neal DE
    Br J Cancer; 1991 Jun; 63(6):967-70. PubMed ID: 1712624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.
    Ye DW; Zheng JF; Qian SX; Ma YJ
    Urol Res; 1993 Jan; 21(1):39-43. PubMed ID: 8096102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection.
    Ye D; Li H; Qian S; Sun Y; Zheng J; Ma Y
    J Urol; 1998 Dec; 160(6 Pt 1):2025-8; discussion 2029. PubMed ID: 9817315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of frameshift mutations in the bax gene in renal cell cancer (RCC) and transitional cell cancer (TCC).
    Bilim VN; Kawasaki T; Takahashi K; Tomita Y
    Anticancer Res; 1998; 18(3A):1655-9. PubMed ID: 9673385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetics of human bladder carcinomas.
    Perucca D; Szepetowski P; Simon MP; Gaudray P
    Cancer Genet Cytogenet; 1990 Oct; 49(2):143-56. PubMed ID: 2208052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutations and MDM-2 amplification in renal cell cancers.
    Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gene sequence analysis of suppressor oncogene p53 in bladder carcinoma].
    Rosell Costa D; García-Foncillas Lopez J; Díez-Caballero Vivas-Pérez JI; Garcia-Tapia JA; Sanz Pérez G; Abad Alonso FD; Martín-Marquina Aspiunza A; Rodríguez-Rubio Cortadellas FI; Robles García JE; Zudaire Bergera JJ; Berián Polo JM
    Actas Urol Esp; 1998; 22(7):552-6. PubMed ID: 9807864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [p53 mutation in phenacetin-induced urothelial carcinomas].
    Petersen I; Ohgaki H; Ludeke BI; Kleihues P
    Verh Dtsch Ges Pathol; 1993; 77():252-5. PubMed ID: 7511292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene p53 mutation and prognosis in bladder tumors].
    Polito M; Minardi D; Giannulis I; Montironi R; Yehia M; Cristalli AF; Muzzonigro G
    Arch Ital Urol Androl; 1997 Feb; 69 Suppl 1():65-8. PubMed ID: 9181926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.